This article is more than 5 years old. Information may no longer be current.

Hormonal controls may play smaller role in MGD than previously thought

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Researchers discovered no significant differences between pre- and post-menopausal women with meibomian gland dysfunction, suggesting that hormonal controls might play a lesser role than previously thought, according to a poster presented at the American Academy of Optometry meeting in New Orleans.

Jennifer S. Harthan, OD, FAAO, and colleagues evaluated 56 females older than 40 years and 42 females younger than 40 years.

Jennifer S. Harthan

Patients were administered the Ocular Surface Disease Index (OSDI), Total Ocular Symptom Score and a nine-symptom questionnaire regarding frequency and intensity.

No significant differences were found between the two cohorts for meibomian gland expression and OSDI.

In the younger group, 54.8% had meibomian gland dysfunction (MGD), and in the older group, 60.7%.

The women older than 40 reported more constant frequency of their worst symptoms and higher sensitivity to bright light, according to researchers.

“Past perceptions of dry eye patient demographics may age-bias clinicians to underdiagnose MGD,” Harthan told Primary Care Optometry News. – by Abigail Sutton

Disclosure: Harthan reported she is a consultant for Allergan, Bausch + Lomb, Contamac and Metro Optics.